ESMO Virtual Congress 2020: Invited Discussant LBA26 Oral HIF-2α Inhibitor MK-6482 for Von Hippel-Lindau Disease–Associated ccRCC and 703MO – Spatial Dynamics and Genomic Alterations in Renal Cell Carcinoma

(UroToday.com) The first abstract discussed was LBA26 – Phase 2 Study of the Oral HIF-2α Inhibitor MK-6482 for Von Hippel-Lindau (VHL) Disease–Associated Clear Cell Renal Cell Carcinoma (ccRCC): Update on RCC and Non-RCC Disease.